King Pharmaceuticals KG Liability for Claims and Claims Adjustment Expense

Liability for Claims and Claims Adjustment Expense at other companies

KKR & Co.KKR

$386.7M+9.6%

Arch Capital GroupACGL

——

Everest GroupEG

——

SiriusPointSPNT

——

Skyward Specialty Insurance Group, Inc.SKWD

——

Selective Insurance GroupSIGI

——

Segments

By product

See full

Total$416.57M—

Other reconciling items excluded from loss development tables$148.48M—

European Hospital Liability$88.89M—

General Liability$82.07M—

International$28.77M—

Commercial Auto Liability$20.29M—

By segment

See full

AmTrust Reinsurance$554.51M—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's liability for claims and claims adjustment expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's liability for claims and claims adjustment expense?: King Pharmaceuticals (KG) reported liability for claims and claims adjustment expense of $593.35M in Q1 2026.